2022 was another big year for Shockwave and Q4 was no exception! On Twitter, the first Shockwave L6 cases were posted by physicians who participated in its limited release and it was great to see their excitement for our new large-vessel peripheral IVL catheter launching soon in the U.S.! At VIVA ‘22, Dr. Ehrin Armstrong presented the final 1,373 patient cohort data from the Disrupt PAD III Observational Study; this larger patient data set reinforces the predictability of Shockwave IVL and its ability to consistently modify calcium across vessel beds, challenging lesions and complex patients. Additionally, international calcium experts shared their real-world experiences with the safety and efficacy of coronary IVL across different calcium morphologies, including concentric, eccentric and nodular calcium. Check out that and more in the new PulsePoint Newsletter!
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Reimbursement,
Treating Different Ca++ Morphologies,
Female vs. Male Outcomes,
Empower CAD
Updated SCAI guidance includes Coronary IVL as a treatment option in all U.S. cath labs regardless of surgical backup status.
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Shockwave C2
CMS Corrects Error for IVL Procedures in ASC Setting – Retroactive TPT Payment Eligible for 2022
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Shockwave C2,
Reimbursement
Improved Reimbursement for Coronary IVL in Germany
Für eine deutschsprachige Version klicken Sie HIER
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Shockwave C2,
Reimbursement
Verbesserte Kostenerstattung für koronare IVL in Deutschland
For an English language version, click HERE
Read More
Topics:
Coronary IVL,
IVL Technology,
SWAV News,
Shockwave C2,
Reimbursement
Just five years ago, we were a start-up, commencing the launch of our pioneering treatment for calcified cardiovascular disease. Today we are a public company with customers in over 60 countries and a robust pipeline of technologies in various stages of development. Backed by solid clinical results, our intravascular lithotripsy (IVL) system has been used to treat more than 120,000 patients worldwide and we have every reason to believe it will help millions.
Read More
Topics:
IVL Technology,
SWAV News
It was smooth sailing for Shockwave this summer! Thank you to everyone who made Q3 unforgettable; but before we get cozy for the holidays, let’s reflect on the events that made the quarter one to remember. This year’s TCT was particularly momentous, as we announced the first prospective, female-only study of coronary interventions, EMPOWER CAD. We also explored tips and tricks for IVL with guide extension catheter usage with Dr. Stephan Heo and debated different approaches to modifying nodular calcium with an expert panel. Read up on the latest Shockwave IVL peer-written publications and more in the Q3 PulsePoint Newsletter.
Read More
Topics:
Coronary IVL,
Peripheral IVL,
IVL Technology,
Coronary Clinical Data,
Peripheral Conferences,
Peripheral Clinical Data,
SWAV News,
Shockwave C2,
Coronary Conferences,
Shockwave S4,
PulsePoint Newsletter,
Calcium Corner,
Shockwave M5 & Shockwave M5+,
Female vs. Male Outcomes,
Empower CAD
